BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 31468077)

  • 1. Influence of intranasal exposure of MPTP in multiple doses on liver functions and transition from non-motor to motor symptoms in a rat PD model.
    Datta I; Mekha SR; Kaushal A; Ganapathy K; Razdan R
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Feb; 393(2):147-165. PubMed ID: 31468077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
    Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
    Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MPTP-induced dopaminergic neurotoxicity in mouse brain is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling.
    Fujita A; Fujita Y; Pu Y; Chang L; Hashimoto K
    Psychopharmacology (Berl); 2020 Jan; 237(1):83-92. PubMed ID: 31418048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
    Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
    Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The risk is in the air: Intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease.
    Prediger RD; Batista LC; Medeiros R; Pandolfo P; Florio JC; Takahashi RN
    Exp Neurol; 2006 Dec; 202(2):391-403. PubMed ID: 16908021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress.
    Paul R; Choudhury A; Kumar S; Giri A; Sandhir R; Borah A
    PLoS One; 2017; 12(2):e0171285. PubMed ID: 28170429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson's disease.
    Castro AA; Ghisoni K; Latini A; Quevedo J; Tasca CI; Prediger RD
    Behav Brain Res; 2012 Apr; 229(1):208-15. PubMed ID: 22266923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of intranasal infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) upon catecholamine concentrations within olfactory bulbs and corpus striatum of male mice.
    Dluzen DE; Kefalas G
    Brain Res; 1996 Nov; 741(1-2):215-9. PubMed ID: 9001725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease?
    Russ H; Mihatsch W; Gerlach M; Riederer P; Przuntek H
    Neurosci Lett; 1991 Feb; 123(1):115-8. PubMed ID: 1712088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antioxidant-Rich Fraction of Urtica dioica Mediated Rescue of Striatal Mito-Oxidative Damage in MPTP-Induced Behavioral, Cellular, and Neurochemical Alterations in Rats.
    Bisht R; Joshi BC; Kalia AN; Prakash A
    Mol Neurobiol; 2017 Sep; 54(7):5632-5645. PubMed ID: 27624385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson's disease.
    Castro AA; Wiemes BP; Matheus FC; Lapa FR; Viola GG; Santos AR; Tasca CI; Prediger RD
    Brain Res; 2013 Jun; 1513():103-16. PubMed ID: 23548600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Octanoic acid prevents reduction of striatal dopamine in the MPTP mouse model of Parkinson's disease.
    Joniec-Maciejak I; Wawer A; Turzyńska D; Sobolewska A; Maciejak P; Szyndler J; Mirowska-Guzel D; Płaźnik A
    Pharmacol Rep; 2018 Oct; 70(5):988-992. PubMed ID: 30107349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk is in the air: an intranasal MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) rat model of Parkinson's disease.
    Prediger RD; Rial D; Medeiros R; Figueiredo CP; Doty RL; Takahashi RN
    Ann N Y Acad Sci; 2009 Jul; 1170():629-36. PubMed ID: 19686204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vinpocetine attenuates MPTP-induced motor deficit and biochemical abnormalities in Wistar rats.
    Sharma S; Deshmukh R
    Neuroscience; 2015 Feb; 286():393-403. PubMed ID: 25514048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
    Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression regulation of Bcl2, Bax and cytochrome-C by geraniol on chronic MPTP/probenecid induced C57BL/6 mice model of Parkinson's disease.
    Rekha KR; Selvakumar GP
    Chem Biol Interact; 2014 Jun; 217():57-66. PubMed ID: 24768735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effect of chinonin in MPTP-induced C57BL/6 mouse model of Parkinson's disease.
    Feng G; Zhang Z; Bao Q; Zhang Z; Zhou L; Jiang J; Li S
    Biol Pharm Bull; 2014; 37(8):1301-7. PubMed ID: 24871044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible role of GABA-B receptor modulation in MPTP induced Parkinson's disease in rats.
    Tyagi RK; Bisht R; Pant J; Kumar P; Majeed AB; Prakash A
    Exp Toxicol Pathol; 2015 Feb; 67(2):211-7. PubMed ID: 25547370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease.
    Prediger RD; Aguiar AS; Rojas-Mayorquin AE; Figueiredo CP; Matheus FC; Ginestet L; Chevarin C; Bel ED; Mongeau R; Hamon M; Lanfumey L; Raisman-Vozari R
    Neurotox Res; 2010 Feb; 17(2):114-29. PubMed ID: 19629612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective effects of stemazole in the MPTP-induced acute model of Parkinson's disease: Involvement of the dopamine system.
    Guo Z; Xu S; Du N; Liu J; Huang Y; Han M
    Neurosci Lett; 2016 Mar; 616():152-9. PubMed ID: 26827716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.